PROSPECTS FOR THE USE OF MESENCHYMAL STEM CELLS IN THE TREATMENT OF CONGENITAL EPIDERMOLYSIS BULLOSA

Epidermolysis bullosa (EB) is a hereditary orphan pathology caused by mutations in genes encoding structural cellular proteins necessary for the integrity of the skin and mucous membranes. As a result of minor mechanical stress, blisters with serous and/or hemorrhagic contents, long-term non-healing wounds and scars form on the skin. Such injuries have a high risk of infectious complications and often lead to disability of the patient. Current treatment methods are primarily palliative in nature and aimed at preventing complications, which emphasizes the relevance in new therapeutic strategies. Mesenchymal stem cells (MSCs) offer a promising therapeutic approach. MSCs are known for their multipotency, immunomodulatory properties, and ability to promote tissue repair, a potential treatment for epidermolysis bullosa. This literature review evaluates the therapeutic potential of MSCs in the treatment of VEB, highlighting key findings from recent studies.